The Simply Good Foods Company (SMPL)
NASDAQ: SMPL · Real-Time Price · USD
30.04
-0.43 (-1.40%)
At close: Aug 1, 2025, 4:00 PM
30.02
-0.02 (-0.05%)
After-hours: Aug 1, 2025, 6:49 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 8 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $39.63, which forecasts a 31.95% increase in the stock price over the next year. The lowest target is $36 and the highest is $43.
Price Target: $39.63 (+31.95%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 3 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 3 | 4 | 4 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $47 → $43 | Buy | Maintains | $47 → $43 | +43.17% | Jul 15, 2025 |
| UBS | UBS | Hold Maintains $41 → $36 | Hold | Maintains | $41 → $36 | +19.86% | Jul 1, 2025 |
| Stifel | Stifel | Strong Buy Maintains $40 → $38 | Strong Buy | Maintains | $40 → $38 | +26.52% | Jun 27, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $43 → $40 | Strong Buy | Maintains | $43 → $40 | +33.18% | Jun 18, 2025 |
| DA Davidson | DA Davidson | Hold Maintains $42 → $38 | Hold | Maintains | $42 → $38 | +26.52% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
1.48B
from 1.33B
Increased by 11.17%
Revenue Next Year
1.53B
from 1.48B
Increased by 3.24%
EPS This Year
1.98
from 1.38
Increased by 43.72%
EPS Next Year
2.11
from 1.98
Increased by 6.34%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.5B | 1.6B | 1.7B | |||
| Avg | 1.5B | 1.5B | 1.6B | |||
| Low | 1.4B | 1.5B | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 14.8% | 8.5% | 11.8% | |||
| Avg | 11.2% | 3.2% | 6.0% | |||
| Low | 6.4% | -2.0% | 0.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.08 | 2.30 | 2.52 | |||
| Avg | 1.98 | 2.11 | 2.32 | |||
| Low | 1.86 | 1.89 | 2.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 50.7% | 15.9% | 19.5% | |||
| Avg | 43.7% | 6.3% | 9.8% | |||
| Low | 34.9% | -4.6% | -1.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.